To include your compound in the COVID-19 Resource Center, submit it here.

Aptosyn exisulind: Phase III data

In a U.S. Phase III trial in 610 patients, Aptosyn plus Taxotere missed the primary endpoint

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE